Eplerenone as an Alternative to Spironolactone for Managing Breast Pain

Introduction to Eplerenone

The European Society of Cardiology recommends switching to eplerenone 25 mg once daily when spironolactone causes breast pain or gynecomastia, as eplerenone maintains mineralocorticoid receptor antagonism with reduced hormone-related side effects 1, 2.

Eplerenone has a 9,11-epoxide group that makes it more selective for the mineralocorticoid receptor, avoiding progestational and antiandrogenic effects that cause breast pain and gynecomastia with spironolactone 3, 4.

Breast discomfort and enlargement occur in 10% of men on spironolactone, but this side effect is infrequent with eplerenone 2, 5.
The European Society of Cardiology guidelines state that the main indication for eplerenone outside post-MI patients is in men with breast discomfort and/or enlargement caused by spironolactone 1, 2.

Start eplerenone at 25 mg once daily as the direct equivalent to spironolactone 25 mg, and check renal function and serum electrolytes before initiating 1, 4, 6.
Target dose is 50 mg once daily, and consider dose up-titration after 4-8 weeks if no contraindications 1, 2, 4.
Follow the same rigorous monitoring schedule as with spironolactone, including rechecking renal function and electrolytes at 1 week and 4 weeks after starting, and monitoring at 1, 2, 3, and 6 months after achieving maintenance dose 1, 2, 4.

Hyperkalemia management is identical for both drugs, with a recommendation to halve the dose to 25 mg on alternate days if potassium rises to >5.5 mmol/L, and to stop eplerenone immediately if potassium rises to ≥6.0 mmol/L 1, 6.

Both medications provide mortality benefit, though spironolactone showed slightly greater effect in trials, with a 30% reduction in mortality in RALES and a 15% reduction in mortality in EPHESUS for eplerenone 2, 6.
The difference in efficacy is likely due to trial populations rather than drug potency, and eplerenone remains guideline-recommended as equivalent therapy when spironolactone is not tolerated 1, 5.